Journal of Leukocyte Biology BioLegend: Treg, Th17, Stem Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0607436 on October 10, 2007

Published online before print October 10, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0607436v1
83/1/112    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nolte-’t Hoen, E. N. M.
Right arrow Articles by Wauben, M. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nolte-’t Hoen, E. N. M.
Right arrow Articles by Wauben, M. H. M.
(Journal of Leukocyte Biology. 2008;83:112-121.)
© 2008 by Society for Leukocyte Biology

Identification and monitoring of effector and regulatory T cells during experimental arthritis based on differential expression of CD25 and CD134

Esther N. M. Nolte-’t Hoen*,1, Elmieke P. J. Boot{dagger},{ddagger},1,2, Josée P. A. Wagenaar-Hilbers{dagger}, Jolanda H. M. van Bilsen{dagger},3, Ger J. A. Arkesteijn{dagger}, Gert Storm{ddagger}, Linda A. Everse{dagger},{ddagger},4, Willem van Eden{dagger} and Marca H. M. Wauben*,5

Departments of
* Biochemistry and Cell Biology and
{dagger} Infectious Diseases and Immunology, Faculty of Veterinary Medicine, and
{ddagger} Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

5 Correspondence: Department of Biochemistry & Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584CM Utrecht, The Netherlands. E-mail: m.h.m.wauben{at}vet.uu.nl

Major problems in the analysis of CD4+ effector cell and regulatory T cell (Treg) populations in an activated immune system are caused by the facts that both cell types can express CD25 and that the discriminatory marker forkhead box p3 can only be analyzed in nonviable (permeabilized) cells. Here, we show that CD134 (OX40) can be used as a discriminatory marker combined with CD25 to isolate and characterize viable CD4+ effector cells and Tregs. Before and during adjuvant arthritis in rats, coexpression of CD134 and CD25 identified activated Tregs consistently, as these T cells proliferated poorly to disease-associated antigens and were suppressive in vitro and in vivo. Depending on the time of isolation and location, CD4+ T cell populations expressing CD134 or CD25 contained effector/memory T cells. Analysis of the function, phenotype, and amount of the CD4+ T cell subsets in different lymph node stations revealed spatiotemporal differences in effector cell and Treg compartments during experimental arthritis.

Key Words: FoxP3 • immune regulation • kinetics • lymph nodes






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Leukocyte Biology.